Aripiprazole Tablet
Product Images NDC 71335-1513

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1513). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure4 (Aripiprazole Fig4)

A chart depicting aripiprazole fold change and 90% confidence intervals showing pharmacokinetic parameters AUC and Cmax for special populations. The variables include CYP2D6 metabolism status, gender, age groups, degrees of hepatic impairment, and severe renal impairment, with changes relative to a reference group on the x-axis.*

FDA Label Image

Figure5 (Aripiprazole Fig5)

A pharmacokinetic chart showing dehydro-aripiprazole fold change with 90% confidence intervals. It compares variables including CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment. The x-axis represents fold change relative to the reference for area under the curve (AUC) and maximum concentration (Cmax).*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of Aripiprazole shown as a molecular diagram with detailed bonding and atom placement, including chlorine-substituted aromatic rings and a quinolinone moiety.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold change and 90% confidence intervals of Aripiprazole's AUC and Cmax when co-administered with various inhibitors and inducers. The graph plots change relative to reference (without interacting drug) on the x-axis, with drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam listed on the y-axis.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A forest plot chart titled 'Effect of Other Drugs on Aripiprazole' showing the change in dehydro-aripiprazole fold change and 90% confidence interval across various interacting drugs. The vertical axis lists drug categories including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers like famotidine, and others such as valproate, lithium, and lorazepam. The horizontal axis represents the change relative to reference without interacting drug, ranging from approximately 0.0 to 3.0.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A chart illustrating the effect of Aripiprazole on various drugs, showing fold change and 90% confidence intervals. The graph compares pharmacokinetic parameters such as AUC and Cmax for drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, relative to a reference without the interacting drug.*

FDA Label Image

Figure6 (Aripiprazole Fig 06)

A Kaplan-Meier curve chart depicting the proportion of subjects with relapse over time. The x-axis represents the number of weeks on Aripiprazole or placebo treatment, while the y-axis shows the proportion with relapse. The chart includes counts of subjects at risk for each time point for both Aripiprazole and placebo groups.*

FDA Label Image

Aripiprazole_fig_07 (Aripiprazole Fig 07)

A Kaplan-Meier curve comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization, and the y-axis shows proportion with relapse. The number of subjects at risk is listed below the x-axis for each group across various time points.*

FDA Label Image

Aripiprazole_fig_08 (Aripiprazole Fig 08)

A line graph comparing the proportion with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 364 days, with the number of subjects at risk noted below. The y-axis shows the proportion with relapse, ranging from 0.0 to 1.0. Aripiprazole is represented by a blue line, and placebo by a red dashed line.*

FDA Label Image

Label Image (Lbl713351513)

Aripiprazole 5 mg tablet label from Bryant Ranch Prepack, packaged in Burbank, CA. The label compares the product to Abilify 5 mg tablet by Ajanta Pharma Limited. It indicates a tablet dosage form, quantity of 30, and includes storage instructions at 20°-25°C (68°-77°F). The NDC 71335-1513 is highlighted along with a barcode and a note to keep all drugs out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.